RXPC is Dead. R.I.P.
Stock Registration has been revoked and the Corporation has been voided by the state of Delaware. All patents for DR70 have expired. Radient's patent agent has resigned and the patent office has no current address for Radient. Currently no company using the DR-70 fibrin test is required to pay royalties or licensing fees to Radient.
Since the group of Aussies have taken over management of Radient Pharmaceuticals, they have transferred all remaining assets to cstamdl.com, their personal company based in Hong Kong. The cstamdl site claims all previous clinical trial data as their own, and they claim to have a manufacturing facility in the USA named AMDL and show pictures of the facility. Radient Pharmaceuticals is left with nothing but debt and disgruntled former shareholders. No company is merging with, taking over, or acquiring Radient.